Skip to content

Study · Not a test of the peptide alone · 2025

5 results

Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study.

Vozza A, Triggiani D, Fanelli M, Lisco G, Coletto D, Custodero C, Volpe S, Racaniello D, Colaianni V, Lavarra V, Maggipinto R, Portacci A, Tortorella C, Moschetta A, Piazzolla G

Frontiers in endocrinology25 Sept 2025Cited by 5 (Europe PMC)

PMID41079186 (opens in a new tab)PMCIDPMC12507565 (opens in a new tab)DOI10.3389/fendo.2025.1674308 (opens in a new tab)PepBankPUB-41079186
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

IntroductionGlucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for their efficacy in glycemic control and weight reduction, but patient response is heterogeneous and predictors of weight loss remain insufficiently defined. This 52-week prospective, observational study aimed to identify predictors of weight reduction (≥5% from baseline) in patients with type 2 diabetes mellitus (T2D) undergoing GLP-1RA therapy (semaglutide or dulaglutide, including oral formulations).MethodsA total of 194 adults with T2D initiating GLP-1RA therapy were evaluated at baseline, and after 6, and 12 months of therapy. To identify predictors of weight loss, variables differing between Responders (weight loss ≥5% than baseline) and Non-Responders were evaluated by ROC analysis and tested in univariate and multivariate logistic regression models adjusted for age, gender, GLP-1RA type and dosage.ResultsAt 6 and 12 months, 58% and 49% of patients, respectively, achieved the primary outcome. Responders at 12 months exhibited elevated BMI, waist circumference, hepatic steatosis indices, fat mass, and insulin levels at baseline, along with reduced muscle-to-fat and muscle-to-visceral adipose tissue ratios. Moreover, female gender, younger age, shorter disease duration, and non-use of metformin prior to enrollment were significantly associated with response. Notably, early response at 6 months strongly predicted 12-month success.ConclusionsOur results highlight a valuable interplay between body composition, liver involvement, and the incretin response, also suggesting a maximal synergistic effect between metformin and GLP-1RAs when treatments are initiated concurrently rather than sequentially. These data provide valuable insights for the development of individualized treatment strategies.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes starting GLP-1 receptor agonist therapy (semaglutide or dulaglutide), 58% achieved weight loss of at least 5% at 6 months.

    In plain wordsAmong adults with type 2 diabetes starting semaglutide or dulaglutide, 58% lost at least 5% of body weight by 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseProportion with at least 5% weight loss at 6 months
    Study

    n = 194

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Responders at 6 months
    58%
    semaglutide or dulaglutide

    Source sentences

    Summary
    At 6 and 12 months, 58% and 49% of patients, respectively, achieved the primary outcome.
    2 context sentences
    Summary · context
    This 52-week prospective, observational study aimed to identify predictors of weight reduction (≥5% from baseline) in patients with type 2 diabetes mellitus (T2D) undergoing GLP-1RA therapy (semaglutide or dulaglutide, including oral formulations).
    Summary · context
    A total of 194 adults with T2D initiating GLP-1RA therapy were evaluated at baseline, and after 6, and 12 months of therapy.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes starting GLP-1 receptor agonist therapy (semaglutide or dulaglutide), 49% achieved weight loss of at least 5% at 12 months.

    In plain wordsAmong adults with type 2 diabetes starting semaglutide or dulaglutide, 49% lost at least 5% of body weight by 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseProportion with at least 5% weight loss at 12 months
    Study

    n = 194

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Responders at 12 months
    49%
    semaglutide or dulaglutide

    Source sentences

    Summary
    At 6 and 12 months, 58% and 49% of patients, respectively, achieved the primary outcome.
    2 context sentences
    Summary · context
    This 52-week prospective, observational study aimed to identify predictors of weight reduction (≥5% from baseline) in patients with type 2 diabetes mellitus (T2D) undergoing GLP-1RA therapy (semaglutide or dulaglutide, including oral formulations).
    Summary · context
    A total of 194 adults with T2D initiating GLP-1RA therapy were evaluated at baseline, and after 6, and 12 months of therapy.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneObservational studyOther

    In adults with type 2 diabetes on GLP-1 receptor agonists (semaglutide or dulaglutide), 12-month responders had higher baseline BMI, waist circumference, hepatic steatosis indices, fat mass and insulin levels, and lower muscle-to-fat ratios.

    In plain wordsAmong adults with type 2 diabetes on semaglutide or dulaglutide, people who lost weight started with higher BMI, waist size, fat mass and insulin levels.

    Peptide
    Semaglutide
    Outcome
    Not applicableBaseline body composition features of 12-month responders
    Study

    n = 194

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Responders at 12 months exhibited elevated BMI, waist circumference, hepatic steatosis indices, fat mass, and insulin levels at baseline, along with reduced muscle-to-fat and muscle-to-visceral adipose tissue ratios.
    2 context sentences
    Summary · context
    This 52-week prospective, observational study aimed to identify predictors of weight reduction (≥5% from baseline) in patients with type 2 diabetes mellitus (T2D) undergoing GLP-1RA therapy (semaglutide or dulaglutide, including oral formulations).
    Summary · context
    A total of 194 adults with T2D initiating GLP-1RA therapy were evaluated at baseline, and after 6, and 12 months of therapy.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneObservational studyOther

    In adults with type 2 diabetes on GLP-1 receptor agonists (semaglutide or dulaglutide), female gender, younger age, shorter disease duration and non-use of metformin before enrolment were significantly associated with response.

    In plain wordsIn adults on semaglutide or dulaglutide, being female, younger, having shorter diabetes duration and not taking metformin were linked to weight loss.

    Peptide
    Semaglutide
    Outcome
    Not applicableDemographic and treatment predictors of weight-loss response
    Study

    n = 194

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Moreover, female gender, younger age, shorter disease duration, and non-use of metformin prior to enrollment were significantly associated with response.
    2 context sentences
    Summary · context
    This 52-week prospective, observational study aimed to identify predictors of weight reduction (≥5% from baseline) in patients with type 2 diabetes mellitus (T2D) undergoing GLP-1RA therapy (semaglutide or dulaglutide, including oral formulations).
    Summary · context
    A total of 194 adults with T2D initiating GLP-1RA therapy were evaluated at baseline, and after 6, and 12 months of therapy.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Semaglutide aloneObservational studyOther

    In adults with type 2 diabetes on GLP-1 receptor agonists (semaglutide or dulaglutide), early response at 6 months strongly predicted success at 12 months.

    In plain wordsAmong adults with type 2 diabetes on semaglutide or dulaglutide, losing weight in the first 6 months strongly predicted success at 12 months.

    Peptide
    Semaglutide
    Outcome
    Not applicableEarly response at 6 months as predictor of 12-month success
    Study

    n = 194

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Notably, early response at 6 months strongly predicted 12-month success.
    2 context sentences
    Summary · context
    This 52-week prospective, observational study aimed to identify predictors of weight reduction (≥5% from baseline) in patients with type 2 diabetes mellitus (T2D) undergoing GLP-1RA therapy (semaglutide or dulaglutide, including oral formulations).
    Summary · context
    A total of 194 adults with T2D initiating GLP-1RA therapy were evaluated at baseline, and after 6, and 12 months of therapy.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07835360

Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirann = 20010 Jul 2026 to est. Jul 2029

Obesity (Disorder) · Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 25 Sept 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.